CRISPR – Fast Initial Growth, But Long-Term Revenues Will Depend on "Wins"PR Newswire (press release)ROCKVILLE, Md., Feb. 13, 2018 /PRNewswire/ — New York City-based market research firm Kalorama Information projects fast revenue growth for … Continue reading
CAR T-Cell Therapy Granted Priority Review for DLBCLCancer NetworkOther CAR T-cell therapies approved in 2017 include tisagenlecleucel for the treatment of children and young adults up to 25 years of age with relapsed or refractory B-cell precursor acu… Continue reading
Synlogic Presents Data from Immuno-Oncology Development Program Demonstrating Potent Anti-Tumor Immunity …Markets InsiderSynlogic (Nasdaq: SYBX), a clinical-stage company applying synthetic biology to probiotics to develop novel living medicines, ann… Continue reading
In Effort to Treat Rare Blinding Disease, Researchers Turn Stem Cells into Blood VesselsUC San Diego HealthPeople who inherit a mutated version of the ATF6 gene are born with a malformed or missing fovea, the eye region responsible for sharp, detailed … Continue reading
Translational research team to test CAR T-cell therapy for pancreatic cancerHealioStand Up To Cancer, in collaboration with the Lustgarten Foundation for Pancreatic Cancer Research, is supporting a new translational research team that will explore how … Continue reading
Medical Xpress |
In effort to treat rare blinding disease, researchers turn stem cells into blood vessels
Medical Xpress Now, in a study published February 13 in Science Signaling, Lin’s team discovered that a chemical compound that activates ATF6 also converts patient-derived stem cells into blood vessels. “We wanted to see if there was a way to correct this gene defect … |